MPLA inhibits release of cytotoxic mediators from human neutrophils while preserving efficient bacterial killing

Immunology and Cell Biology

Volumn 92, Issue 9, 2014, Pages 799-809

  Ruchaud Sparagano, Marie Hélène ^a   Mills, Ross ^b   Scott, Jonathan ^a   Simpson, A John ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYTOKINE; ENZYME; FORMYLMETHIONYLLEUCYLPHENYLALANINE; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; MYELOPEROXIDASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHORYL LIPID A; PROTEIN TYROSINE PHOSPHATASE; SUPEROXIDE; TOLL LIKE RECEPTOR 4; ZYMOSAN; LIPID A; MYD88 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; BLOOD; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDIATOR; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; OPSONIZATION; PHAGOCYTOSIS; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REDUCTION; RESPIRATORY BURST; SERUM; ANALOGS AND DERIVATIVES; IMMUNOLOGY; PSEUDOMONAS INFECTION; SIGNAL TRANSDUCTION;

ALKALINE PHOSPHATASE; HUMANS; INTERLEUKIN-8; LIPID A; LIPOPOLYSACCHARIDES; MYELOID DIFFERENTIATION FACTOR 88; NEUTROPHILS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHAGOCYTOSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TYROSINE PHOSPHATASES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SIGNAL TRANSDUCTION; SUPEROXIDES; TOLL-LIKE RECEPTOR 4;

EID: 84908147067     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.55     Document Type: Article

References (40)

1. Broad A, Jones D, Kirby J. Toll-like receptor (TLR) response tolerance: a key physiological "damage limitation" effect and an important potenti al opportunity for therapy. Curr Med Chem 2006; 13: 2487-2502.
2. Kovach M, Standiford T. The function of neutrophils in sepsis. Curr Opin Infect Dis 2012; 25: 321-327.
3. Haziot A, Ferrero E, Kö ntgen F, Hijiya N, Yamamoto S, Silver J et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4: 407-414.
4. Roger T, Froidevaux C, Le Roy D, Reymond M, Chanson A, Mauri D et al. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci USA 2009; 106: 2348-2352.
5. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1 982; 257: 11808-11815.
6. Chase J, Kubey W, Dulek M, Holmes C, Salit M, Pearson FC et al. Effect of monophosphoryl lipid A on host resistance to bacterial infection. Infect Immun 1986; 53: 711-712.
7. Romero C, Varma T, Hobbs J, Reyes A, Driver B, Sherwood E. The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Infect Immun 2011; 79: 3576-3587.
8. Metkar S, Kim K, Silver J, Goyert S. Differential expression of CD14-dependent and independent pathways for chemokine induction regulates neutrophil trafficking in infection. J Leukoc Biol 2012; 92: 389-396.
9. Jawad I, Luksić I, Rafnsson S. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Glob Health 2012; 2: 10404.
10. Ruchaud-Sparagano M-H, Ruivenkamp CA, Riches PL, Poxton IR, Dransfield I. Differential effects of bacterial lipopolysaccharides upon neutrophil function. FEBS Let t 1998; 430: 363-369.
11. Andrews S, Stephens L, Hawkins P. PI3K class IB pathway in neutrophils. Sci STKE 2007; 2007: cm3.
12. Martin M, Rehani K, Jope R, M ichalek S. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6: 777-784.
13. Nelson R, McCormack R, Fiegel V, Simmons R. Chemotactic deactivation of human neutrophils: evidence for nonspecific and specific components. Infect Immun 1978; 22: 441-444.
14. Ittner A, Block H, Reichel C, Varjosalo M, Gehart H, Su mara G et al. Regulation of PTEN activity by p38d-PKD1 signaling in neutrophils confers inflammatory responses in the lung. J Exp Med 2012; 209: 2229-2246.
15. Heiman D, Astiz M, Rackow E, Rh ein D, Kim Y, Weil M. Monophosphoryl lipid A inhibits neutrophil priming by lipopolysaccharide. J Lab Clin Med 1990; 116: 237-241.
16. Simms H, D'Amico R. Regulation of intracellular polymorphonuclear leukocyte Fc receptors by lipopolysaccharide. Cell Immunol 1994; 157: 525-541.
17. Hirano T, Kodama S, Kawano T, Maeda K, Suzuki M. Monophosphoryl lipid A induced innate immune responses via TLR4 to enhance clearance of nontypeable Haemophilus influenzae and Moraxella catarrhalis from the nasophary nx in mice. FEMS Immunol Med Microbiol 2011; 63: 407-417.
18. Sarti F, Perera G, Hintzen F, Kotti K, Karageorgiou V, Kammona O et al. In vivo evidence of oral vaccination with PLGA na noparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials 2011; 32: 4052-4057.
19. Roquilly A, Gautreau L, Segain J, de Coppet P, Sebille V, Jacqueline C et al. CpG-ODN an d MPLA prevent mortality in a murine model of post-hemorrhage-Staphyloccocus aureus pneumonia. PLoS ONE 2010; 5: e13228.
20. Ismaili J, Rennesson J, Aksoy E, Vekemans J, Vincart B, Amraoui Z et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002; 168: 926-932.
21. Shirey K,Lai W,Scott A,Lipsky M,Mistry P,Pletneva L,et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection Nature, 2013, 497, 498-502.
22. Vosika G, Barr C, Gilbertson D. Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother 1984; 18: 107-112.
23. Astiz M, Galera A, Saha D, Carpati C, Rackow E. Monophosphoryl lipid A protects against gram-positive sepsis and tumor necrosis factor. Shock 1994; 2: 271-274.
24. Kiani A, Tschiersch A, Gaboriau E, Otto F, Seiz A, Knopf H et al. Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood 1997; 90: 1673-1683.
25. Haziot A, Hijiya N, Gangloff S, Silver J, Goyert S. Induction of a novel mechanism of accelerated bacterial clearance b y lipopolysaccharide in CD14-deficient and Toll-like receptor 4-deficient mice. J Immunol 2001; 166: 1075-1078.
26. Salkowski C, Detore G, Vogel S. Lipopolysaccharide and monophosphoryl lipid A differ entially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun 1997; 65: 3239-3247.
27. Okemoto K, Kawasaki K, Hanada K, Miura M, Nishiji ma M. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1. J Immunol 2006; 176: 1203-1208.
28. Kovach N, Yee E, Munfor d R, Raetz C, Harlan J. Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo. J Exp Med 1990; 172: 77-84.
29. Vincent JL. C hapter 16. ARDS and sepsis. Eur Respir Mon 2006; 34: 253-260.
30. Lee WL, Downey GP. Leukocyte elastase: physiological functions and role in acute lung injury. Am J Respir Crit Care Med 2001; 164: 896-904.
31. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casel la CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316: 1628-1632.
32. Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, Mitchell TC. Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J Biol Chem 2009; 284: 31982-31991.
33. Tamassia N, Le Moigne V, Calzetti F, Donini M, Gasperin i S, Ear T et al. The MyD88-independent pathway is not mobilized in human neutrophils stimulated via TLR4. J Immunol 2007; 178: 7344-7356.
34. Dransfield I, Buckle AM, Savill JS, McDowall A, Haslett C, Hogg N. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. J Immunol 1994; 153: 1254-1263.
35. Hampton MB, Vissers MC, Winterbourn CC. A single assay for measuring the rates of phagocytosis and bacterial killing by neutrophils. J Leukoc Biol 1994; 55: 147-152.
36. Conway Morris A, Kefala K, Wilkinson TS, Dhaliwal K, Farrell L, Walsh T et al. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med 2009; 180: 19-28.
37. Ruchaud-Sparagano M-H, Drost EM, Donnelly SC, B ird MI, Haslett C, Dransfield I. Potential pro-inflammatory effects of soluble E-selectin upon neutrophil function. Eur J Immunol 1998; 28: 80-89.
38. Ruchaud-Sparagano M-H, Walker TR, Rossi A G, Haslett C, Dransfield I. Soluble E-selectin acts in synergy with platelet-Activating factor to activate neutrophil beta 2-integrins. Role of tyrosine kinases and Ca2+ mobilization. J Biol Chem 2000; 275: 15758-15764.
39. Palić D, Andreasen CB, Menzel BW, Roth JA. A rapid, direct assay to measure degranulation of primary granules in neutrophils from kidney of fathead minnow (Pimephales promelas Rafinesque, 1820). Fish Shel lfish Immunol 2005; 19: 217-227.
40. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in t he neutrophil leads to its recognition by macrophages. J Clin Invest 1989; 83: 865-875.